ArticlePloS one2026
Water-soluble gadolinium fullerenes Gd@C82-TEGs as a potential magnetic resonance imaging contrast agent.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The water-soluble gadolinium fullerenes Gd@C82-TEGs nanoparticles as a novel magnetic resonance imaging (MRI) contrast agent were fabricated by the metal fullerenes Gd@C82 assembled with tetraethylene glycol (TEG). The loading Gd amount in Gd@C82-TEGs nanoparticles was 8.0 wt%. The average particle size of water-soluble Gd@C82-TEGs nanoparticles was 97 nm and the nanoparticles were uniformly spherical shape and had good dispersibility and no aggregation. The 97 nm spherical shape of Gd@C82-TEG nanoparticles ensured high relaxivity. The proton relaxivity (r1) and transverse relaxivity (r2) were high up to 37.1 mM-1·s-1 and 64.9 mM-1·s-1, which greater than that of commercial Magnevist under the same conditions. The Gd@C82-TEGs nanoparticles exhibited pronounced T1-weighted MRI in vitro. The MRI signal-enhancing efficiency of Gd@C82-TEGs nanoparticles was superior to that of gadolinium diethylenetriamine pentaacetate Gd-DTPA (Magnevist). The Gd@C82-TEGs nanoparticles had no significant effect on cell metabolism and structure, and the survival rate of cells was more than 80%, which indicated that the as-prepared Gd@C82-TEGs nanoparticles were no cytotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.